- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SPRINT BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 02.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.04.2025 | 444 | Xetra Newsboard | Das Instrument 2NH ES0105043006 NATURHOUSE HEALTH EO-,05 EQUITY wird cum Kapitalmassnahme gehandelt am 02.04.2025 und ex Kapitalmassnahme am 03.04.2025 The instrument 2NH ES0105043006 NATURHOUSE HEALTH... ► Artikel lesen | |
| 08.01. | Sprint Bioscience AB: Sprint Biosciences upcoming activities | 88 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) summarizes below the company's upcoming meetings with potential partners and investors during the spring of 2025. In addition, the company will present at international scientific... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,088 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 3,080 | -5,52 % | COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| HALOZYME THERAPEUTICS | 47,150 | +0,68 % | Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline | ||
| ABCELLERA BIOLOGICS | 2,139 | +3,43 % | Why AbCellera Biologics Stock Raced Nearly 6% Higher Today | ||
| GLOW LIFETECH | 0,030 | 0,00 % | Glow LifeTech Corp.: Glow Lifetech Reports 238% YoY Revenue Growth and Near-Breakeven EBITDA in Q1 2025, Marking Third Straight Quarter of 40%+ Sequential Revenue Growth | Toronto, Ontario--(Newsfile Corp. - June 2, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the first quarter... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 189,00 | -1,49 % | Bio-Rad Laboratories-Aktie im Fokus des Cantor Fitzgerald-Berichts | ||
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,490 | +2,05 % | Whitehawk Therapeutics, Inc.: Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., May 8, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals, Inc.: Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS) | Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10-million-patient marketAcquisition advances Paratek's vision... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,600 | 0,00 % | Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates | BURLINGTON, Mass., May 13, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,341 | +6,70 % | Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting | Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs, Inc. - 8-K, Current Report | ||
| COCRYSTAL | 1,470 | +2,80 % | Cocrystal Pharma, Inc. - 8-K, Current Report |
SPRINT BIOSCIENCE AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -16,67 % bei einem Aktienkurs von 0,018 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPRINT BIOSCIENCE AB finden Sie auf Wallstreet Online.